VENTANA MMR RxDx Panel

FDA Premarket Approval P200019

Pre-market Approval Supplement Details

Approval for the ventana mmr rxdx pavel as a cdx for identifying patients with endometrial cancer with dmmr status who may benefit from treatment with jemperli.

DeviceVENTANA MMR RxDx Panel
Generic NameImmunohistochemistry Test, Dna Mismatch Repair (mmr) Protein Assay
ApplicantVentana Medical Systems
Date Received2020-03-16
Decision Date2021-04-22
PMAP200019
SupplementS
Product CodeQNH 
Advisory CommitteePathology
Expedited ReviewNo
Combination Product No
Applicant Address Ventana Medical Systems 1910 East Innovation Park Drive tucson, AZ 85755

Supplemental Filings

Supplement NumberDateSupplement Type
P200019Original Filing
S006 2022-10-14 30-day Notice
S005 2022-07-12 30-day Notice
S004 2022-02-16 Special (immediate Track)
S003 2022-01-28 135 Review Track For 30-day Notice
S002
S001

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.